Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Preservative-Free Tafluprost in Asian Glaucoma Patients
NCT04654611Phase 4
Key facts
- Status
- Completed
- Start
- Feb 2019
- Primary completion
- Feb 2020
- Countries
- 1
- Sponsor
- Tun Hussein Onn National Eye Hospital
- Modality
- Orthosteric Ligands
- Drugs
- tafluprost
- Conditions
- primary open-angle glaucoma (POAG)ocular hypertension
01
Overview
Phase 4, open-label, single-arm trial of tafluprost in primary open-angle glaucoma (POAG) and ocular hypertension, sponsored by Tun Hussein Onn National Eye Hospital. Primary endpoint: National Eye Institute Staining Score at 3 months. Started Feb 2019; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Treatment group
Patients switched to preservative-free tafluprost 0.0015%
03
Who it enrols
Asian patients aged 21 or older with primary open angle glaucoma or ocular hypertension who have corneal disorders (NEI score > 1) due to preserved prostaglandin monotherapy for at least 3 months.
04
Endpoints
Primary
National Eye Institute Staining Score
Beyond the preview
Go deeper on NCT04654611.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04654611.